@article{3103407,
    title = "Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial",
    author = "Anker, S.D. and Butler, J. and Filippatos, G. and Shahzeb Khan, M. and Ferreira, J.P. and Bocchi, E. and Böhm, M. and Brunner-La Rocca, H.P. and Choi, D.-J. and Chopra, V. and Chuquiure, E. and Giannetti, N. and Gomez-Mesa, J.E. and Janssens, S. and Januzzi, J.L. and Gonzalez-Juanatey, J.R. and Merkely, B. and Nicholls, S.J. and Perrone, S.V. and Piña, I.L. and Ponikowski, P. and Senni, M. and Seronde, M.-F. and Sim, D. and Spinar, J. and Squire, I. and Taddei, S. and Tsutsui, H. and Verma, S. and Vinereanu, D. and Zhang, J. and Jamal, W. and Schnaidt, S. and Schnee, J.M. and Brueckmann, M. and Pocock, S.J. and Zannad, F. and Packer, M. and EMPEROR-Preserved Trial Committees and Investigators",
    journal = "European Journal of Heart Failure",
    year = "2020",
    volume = "22",
    number = "12",
    pages = "2383-2392",
    publisher = "John Wiley and Sons Ltd",
    doi = "10.1002/ejhf.2064",
    keywords = "acetylsalicylic acid;  aldosterone antagonist;  amino terminal pro brain natriuretic peptide;  angiotensin receptor antagonist;  anticoagulant agent;  antithrombocytic agent;  beta adrenergic receptor blocking agent;  calcium channel blocking agent;  candesartan;  cardiac glycoside;  digoxin;  dipeptidyl carboxypeptidase inhibitor;  diuretic agent;  empagliflozin;  enkephalinase inhibitor;  hydroxymethylglutaryl coenzyme A reductase inhibitor;  irbesartan;  mineralocorticoid antagonist;  nitric acid derivative;  perindopril;  placebo;  sacubitril plus valsartan;  sodium glucose cotransporter 2 inhibitor;  thiazide diuretic agent;  benzhydryl derivative;  biological marker;  brain natriuretic peptide;  cardiovascular agent;  empagliflozin;  glucoside;  peptide fragment;  pro-brain natriuretic peptide (1-76), adult;  aged;  Article;  atrial fibrillation;  cancer patient;  cardiac patient;  chronic kidney failure;  cohort analysis;  comorbidity;  controlled study;  diabetes mellitus;  disease burden;  double blind procedure;  drug effect;  drug screening;  Europe;  female;  heart failure;  heart failure with preserved ejection fraction;  heart failure with reduced ejection fraction;  heart left ventricle ejection fraction;  hospitalization;  human;  major clinical study;  male;  medical history;  non insulin dependent diabetes mellitus;  North America;  parallel design;  phase 3 clinical trial;  randomized controlled trial;  South and Central America;  symptom;  blood;  clinical trial;  heart failure;  heart stroke volume;  middle aged;  multicenter study;  non insulin dependent diabetes mellitus;  pathophysiology;  very elderly, Aged;  Aged, 80 and over;  Benzhydryl Compounds;  Biomarkers;  Cardiovascular Agents;  Diabetes Mellitus, Type 2;  Double-Blind Method;  Female;  Glucosides;  Heart Failure;  Humans;  Male;  Middle Aged;  Natriuretic Peptide, Brain;  Peptide Fragments;  Sodium-Glucose Transporter 2 Inhibitors;  Stroke Volume",
    abstract = "Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type. natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41–50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499–1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021. © 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology."
}